These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
257 related articles for article (PubMed ID: 24577117)
1. Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial. Vermorken JB; Psyrri A; Mesía R; Peyrade F; Beier F; de Blas B; Celik I; Licitra L Ann Oncol; 2014 Apr; 25(4):801-807. PubMed ID: 24577117 [TBL] [Abstract][Full Text] [Related]
2. p16, HPV, and Cetuximab: What Is the Evidence? Bonner JA; Mesia R; Giralt J; Psyrri A; Keilholz U; Rosenthal DI; Beier F; Schulten J; Vermorken JB Oncologist; 2017 Jul; 22(7):811-822. PubMed ID: 28526718 [TBL] [Abstract][Full Text] [Related]
3. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA; Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666 [TBL] [Abstract][Full Text] [Related]
4. Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab. Rosenthal DI; Harari PM; Giralt J; Bell D; Raben D; Liu J; Schulten J; Ang KK; Bonner JA J Clin Oncol; 2016 Apr; 34(12):1300-8. PubMed ID: 26712222 [TBL] [Abstract][Full Text] [Related]
5. A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Chung CH; Lee JW; Slebos RJ; Howard JD; Perez J; Kang H; Fertig EJ; Considine M; Gilbert J; Murphy BA; Nallur S; Paranjape T; Jordan RC; Garcia J; Burtness B; Forastiere AA; Weidhaas JB Ann Oncol; 2014 Nov; 25(11):2230-2236. PubMed ID: 25081901 [TBL] [Abstract][Full Text] [Related]
6. Demystifying the role of tumor HPV status in recurrent and/or metastatic squamous cell carcinoma of the head and neck. Spreafico A; Amir E; Siu LL Ann Oncol; 2014 Apr; 25(4):760-762. PubMed ID: 24569917 [No Abstract] [Full Text] [Related]
7. Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapy. Pogorzelski M; Ting S; Gauler TC; Breitenbuecher F; Vossebein I; Hoffarth S; Markowetz J; Lang S; Bergmann C; Brandau S; Jawad JA; Schmid KW; Schuler M; Kasper S Cell Death Dis; 2014 Feb; 5(2):e1091. PubMed ID: 24577089 [TBL] [Abstract][Full Text] [Related]
8. Association of human papillomavirus and p16 status with mucositis and dysphagia for head and neck cancer patients treated with radiotherapy with or without cetuximab: Assessment from a phase 3 registration trial. Bonner JA; Giralt J; Harari PM; Baselga J; Spencer S; Bell D; Raben D; Liu J; Schulten J; Ang KK; Rosenthal DI Eur J Cancer; 2016 Sep; 64():1-11. PubMed ID: 27323346 [TBL] [Abstract][Full Text] [Related]
9. A comprehensive evaluation of human papillomavirus positive status and p16INK4a overexpression as a prognostic biomarker in head and neck squamous cell carcinoma. Deng Z; Hasegawa M; Aoki K; Matayoshi S; Kiyuna A; Yamashita Y; Uehara T; Agena S; Maeda H; Xie M; Suzuki M Int J Oncol; 2014 Jul; 45(1):67-76. PubMed ID: 24820457 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-fluorouracil with or without docetaxel: a subset analysis of EORTC 24971 study. Psyrri A; Fortpied C; Koutsodontis G; Avgeris M; Kroupis C; Goutas N; Menis J; Herman L; Giurgea L; Remenár É; Degardin M; Pateras IS; Langendijk JA; van Herpen CML; Awada A; Germà-Lluch JR; Kienzer HR; Licitra L; Vermorken JB Ann Oncol; 2017 Sep; 28(9):2213-2218. PubMed ID: 28651338 [TBL] [Abstract][Full Text] [Related]
11. HPV-associated p16 INK4A expression and response to therapy and survival in selected head and neck cancers. Kanyilmaz G; Ekinci O; Muge A; Celik S; Ozturk F Asian Pac J Cancer Prev; 2015; 16(1):253-8. PubMed ID: 25640361 [TBL] [Abstract][Full Text] [Related]
12. The current and future impact of human papillomavirus on treatment of squamous cell carcinoma of the head and neck. Psyrri A; Rampias T; Vermorken JB Ann Oncol; 2014 Nov; 25(11):2101-2115. PubMed ID: 25057165 [TBL] [Abstract][Full Text] [Related]
13. Surgical salvage improves overall survival for patients with HPV-positive and HPV-negative recurrent locoregional and distant metastatic oropharyngeal cancer. Guo T; Qualliotine JR; Ha PK; Califano JA; Kim Y; Saunders JR; Blanco RG; D'Souza G; Zhang Z; Chung CH; Kiess A; Gourin CG; Koch W; Richmon JD; Agrawal N; Eisele DW; Fakhry C Cancer; 2015 Jun; 121(12):1977-84. PubMed ID: 25782027 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Licitra L; Mesia R; Rivera F; Remenár É; Hitt R; Erfán J; Rottey S; Kawecki A; Zabolotnyy D; Benasso M; Störkel S; Senger S; Stroh C; Vermorken JB Ann Oncol; 2011 May; 22(5):1078-1087. PubMed ID: 21048039 [TBL] [Abstract][Full Text] [Related]
15. Targeted next-generation sequencing identifies molecular subgroups in squamous cell carcinoma of the head and neck with distinct outcome after concurrent chemoradiation. Tinhofer I; Stenzinger A; Eder T; Konschak R; Niehr F; Endris V; Distel L; Hautmann MG; Mandic R; Stromberger C; Weichert W; Budach V Ann Oncol; 2016 Dec; 27(12):2262-2268. PubMed ID: 27681865 [TBL] [Abstract][Full Text] [Related]
16. The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Chau NG; Perez-Ordonez B; Zhang K; Pham NA; Ho J; Zhang T; Ludkovski O; Wang L; Chen EX; Tsao MS; Kamel-Reid S; Siu LL Head Neck Oncol; 2011 Feb; 3():11. PubMed ID: 21352589 [TBL] [Abstract][Full Text] [Related]
17. p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma. Chung CH; Zhang Q; Kong CS; Harris J; Fertig EJ; Harari PM; Wang D; Redmond KP; Shenouda G; Trotti A; Raben D; Gillison ML; Jordan RC; Le QT J Clin Oncol; 2014 Dec; 32(35):3930-8. PubMed ID: 25267748 [TBL] [Abstract][Full Text] [Related]
18. Phase II study of cetuximab in combination with cisplatin and radiation in unresectable, locally advanced head and neck squamous cell carcinoma: Eastern cooperative oncology group trial E3303. Egloff AM; Lee JW; Langer CJ; Quon H; Vaezi A; Grandis JR; Seethala RR; Wang L; Shin DM; Argiris A; Yang D; Mehra R; Ridge JA; Patel UA; Burtness BA; Forastiere AA Clin Cancer Res; 2014 Oct; 20(19):5041-51. PubMed ID: 25107914 [TBL] [Abstract][Full Text] [Related]
19. Molecular subclassification determined by human papillomavirus and epidermal growth factor receptor status is associated with the prognosis of oropharyngeal squamous cell carcinoma. Nakano T; Yamamoto H; Nakashima T; Nishijima T; Satoh M; Hatanaka Y; Shiratsuchi H; Yasumatsu R; Toh S; Komune S; Oda Y Hum Pathol; 2016 Apr; 50():51-61. PubMed ID: 26997438 [TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. Rischin D; Young RJ; Fisher R; Fox SB; Le QT; Peters LJ; Solomon B; Choi J; O'Sullivan B; Kenny LM; McArthur GA J Clin Oncol; 2010 Sep; 28(27):4142-8. PubMed ID: 20697079 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]